XML 46 R29.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Identifiable Intangible Assets and Goodwill (Tables) | 9 Months Ended
--- | ---
Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of Finite-Lived Intangible Assets |
The following table provides the components of Identifiable intangible assets:
|  | October 1, 2017 |  | December 31, 2016
(MILLIONS OF DOLLARS) |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Developed technology rights(a) |  | $ | 89,585 |  |  | $ | (53,960 | ) |  | $ | 35,625 |  |  | $ | 83,390 |  |  | $ | (49,650 | ) |  | $ | 33,740 |
Brands |  | 2,135 |  |  | (1,127 | ) |  | 1,008 |  |  | 2,092 |  |  | (1,032 | ) |  | 1,060 |
Licensing agreements and other |  | 1,930 |  |  | (1,071 | ) |  | 859 |  |  | 1,869 |  |  | (1,005 | ) |  | 864 |
|  | 93,650 |  |  | (56,158 | ) |  | 37,492 |  |  | 87,351 |  |  | (51,687 | ) |  | 35,664 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Brands and other |  | 6,937 |  |  |  |  |  | 6,937 |  |  | 6,883 |  |  |  |  |  | 6,883 |
IPR&D(a) |  | 5,292 |  |  |  |  |  | 5,292 |  |  | 10,101 |  |  |  |  |  | 10,101 |
|  | 12,229 |  |  |  |  |  | 12,229 |  |  | 16,984 |  |  |  |  |  | 16,984 |
Identifiable intangible assets(b) |  | $ | 105,879 |  |  | $ | (56,158 | ) |  | $ | 49,721 |  |  | $ | 104,335 |  |  | $ | (51,687 | ) |  | $ | 52,648 |
(a) | The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A) and (v) impairments of Developed technology rights (see Note 4).
(b) The decrease in I dentifiable intangible assets, less accumulated amortization, is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A), as well as impairments of Developed technology rights (see Note 4), partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E).
Schedule of Indefinite Lived Intangible Assets |
The following table provides the components of Identifiable intangible assets:
|  | October 1, 2017 |  | December 31, 2016
(MILLIONS OF DOLLARS) |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Developed technology rights(a) |  | $ | 89,585 |  |  | $ | (53,960 | ) |  | $ | 35,625 |  |  | $ | 83,390 |  |  | $ | (49,650 | ) |  | $ | 33,740 |
Brands |  | 2,135 |  |  | (1,127 | ) |  | 1,008 |  |  | 2,092 |  |  | (1,032 | ) |  | 1,060 |
Licensing agreements and other |  | 1,930 |  |  | (1,071 | ) |  | 859 |  |  | 1,869 |  |  | (1,005 | ) |  | 864 |
|  | 93,650 |  |  | (56,158 | ) |  | 37,492 |  |  | 87,351 |  |  | (51,687 | ) |  | 35,664 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Brands and other |  | 6,937 |  |  |  |  |  | 6,937 |  |  | 6,883 |  |  |  |  |  | 6,883 |
IPR&D(a) |  | 5,292 |  |  |  |  |  | 5,292 |  |  | 10,101 |  |  |  |  |  | 10,101 |
|  | 12,229 |  |  |  |  |  | 12,229 |  |  | 16,984 |  |  |  |  |  | 16,984 |
Identifiable intangible assets(b) |  | $ | 105,879 |  |  | $ | (56,158 | ) |  | $ | 49,721 |  |  | $ | 104,335 |  |  | $ | (51,687 | ) |  | $ | 52,648 |
(a) | The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A) and (v) impairments of Developed technology rights (see Note 4).
(b) The decrease in I dentifiable intangible assets, less accumulated amortization, is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A), as well as impairments of Developed technology rights (see Note 4), partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E).
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment |
Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
|  | October 1, 2017
|  | IH |  | EH |  | WRD
Developed technology rights |  | 68 | % |  | 32 | % |  | — | %
Brands, finite-lived |  | 75 | % |  | 25 | % |  | — | %
Brands, indefinite-lived |  | 71 | % |  | 29 | % |  | — | %
IPR&D |  | 80 | % |  | 13 | % |  | 7 | %
Schedule of Goodwill |
The following table provides the components of and changes in the carrying amount of Goodwill:
(MILLIONS OF DOLLARS) |  | IH |  | EH |  | Total
Balance, December 31, 2016 |  | $ | 30,134 |  |  | $ | 24,315 |  |  | $ | 54,449 |
Additions(a) |  | 572 |  |  | 92 |  |  | 664 |
Other(b) |  | 491 |  |  | 475 |  |  | 966 |
Balance, October 1, 2017 |  | $ | 31,197 |  |  | $ | 24,882 |  |  | $ | 56,078 |
(a) | IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see Note 2A).
(b) Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.

X
- Definition [Table Text Block] for Identifiable intangible assets as a percentage of total identifiable intangible assets less accumulated amortization, by segment [Table] + References No definition available. + Details
Name: | pfe_IdentifiableintangibleassetsasapercentageoftotalidentifiableintangibleassetslessaccumulatedamortizationbysegmentTableTextBlock
Namespace Prefix: | pfe_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration